Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.
2.

Effects of acute memantine administration on MATRICS Consensus Cognitive Battery performance in psychosis: Testing an experimental medicine strategy.

Bhakta SG, Chou HH, Rana B, Talledo JA, Balvaneda B, Gaddis L, Light GA, Swerdlow NR.

Psychopharmacology (Berl). 2016 Jun;233(12):2399-410. doi: 10.1007/s00213-016-4291-0.

3.

Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.

Lee MR, Wehring HJ, McMahon RP, Liu F, Linthicum J, Verbalis JG, Buchanan RW, Strauss GP, Rubin LH, Kelly DL.

Schizophr Res. 2016 Apr;172(1-3):165-8. doi: 10.1016/j.schres.2016.02.014.

PMID:
26879587
4.

D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.

Schade S, Paulus W.

Int J Neuropsychopharmacol. 2016 Apr 20;19(4). pii: pyv102. doi: 10.1093/ijnp/pyv102. Review.

5.

Effect of intranasal oxytocin administration on psychiatric symptoms: A meta-analysis of placebo-controlled studies.

Hofmann SG, Fang A, Brager DN.

Psychiatry Res. 2015 Aug 30;228(3):708-14. doi: 10.1016/j.psychres.2015.05.039.

6.

A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia.

Velligan DI, Roberts D, Mintz J, Maples N, Li X, Medellin E, Brown M.

Schizophr Res. 2015 Jul;165(2-3):175-80. doi: 10.1016/j.schres.2015.04.008.

7.

GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders.

Young JW, Kamenski ME, Higa KK, Light GA, Geyer MA, Zhou X.

Neuropsychopharmacology. 2015 Nov;40(12):2715-26. doi: 10.1038/npp.2015.120.

8.

Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.

Lencz T, Malhotra AK.

Mol Psychiatry. 2015 Jul;20(7):820-6. doi: 10.1038/mp.2015.28.

9.

The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Cohen SM, Tsien RW, Goff DC, Halassa MM.

Schizophr Res. 2015 Sep;167(1-3):98-107. doi: 10.1016/j.schres.2014.12.026. Review.

10.

The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond.

Balu DT, Coyle JT.

Curr Opin Pharmacol. 2015 Feb;20:109-15. doi: 10.1016/j.coph.2014.12.004. Review.

11.

Synaptic plasticity, neural circuits, and the emerging role of altered short-term information processing in schizophrenia.

Crabtree GW, Gogos JA.

Front Synaptic Neurosci. 2014 Nov 25;6:28. doi: 10.3389/fnsyn.2014.00028. Review.

12.

Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

Buchanan RW, Weiner E, Kelly DL, Gold JM, Keller WR, Waltz JA, McMahon RP, Gorelick DA.

Schizophr Bull. 2015 Jul;41(4):900-8. doi: 10.1093/schbul/sbu151.

13.

The common inflammatory etiology of depression and cognitive impairment: a therapeutic target.

Allison DJ, Ditor DS.

J Neuroinflammation. 2014 Sep 2;11:151. doi: 10.1186/s12974-014-0151-1. Review.

14.

Pregnenolone sulfate as a modulator of synaptic plasticity.

Smith CC, Gibbs TT, Farb DH.

Psychopharmacology (Berl). 2014 Sep;231(17):3537-56. doi: 10.1007/s00213-014-3643-x. Review.

15.

Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.

Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, Dickerson FB.

Schizophr Res. 2014 Aug;157(1-3):84-9. doi: 10.1016/j.schres.2014.04.037. Review.

16.

Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options.

Chue P, Lalonde JK.

Neuropsychiatr Dis Treat. 2014 May 8;10:777-89. doi: 10.2147/NDT.S43404. Review.

17.

Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.

Gruber O, Chadha Santuccione A, Aach H.

Front Psychiatry. 2014 Apr 3;5:32. doi: 10.3389/fpsyt.2014.00032. Review.

18.

William T. Carpenter Jr: 35 years of clinical trials.

Buchanan RW.

Schizophr Bull. 2014 Mar;40 Suppl 2:S160-3. doi: 10.1093/schbul/sbt143.

19.

Progress in the study of negative symptoms.

Kirkpatrick B.

Schizophr Bull. 2014 Mar;40 Suppl 2:S101-6. doi: 10.1093/schbul/sbt158.

20.
Items per page

Supplemental Content

Support Center